PERIPHERAL ARTERIAL DISEASE
|
|
- Cecilia Wells
- 6 years ago
- Views:
Transcription
1 ORIGINAL INVESTIGATION Cystatin C and Incident Peripheral Arterial Disease Events in the Elderly Results From the Cardiovascular Health Study Ann M. O Hare, MD, MA; Anne B. Newman, MD, MPH; Ronit Katz, PhD; Linda F. Fried, MD; Catherine O. Stehman-Breen, MD; Stephen L. Seliger, MD; David S. Siscovick, MD; Michael G. Shlipak, MD, MPH Background: The association of cystatin C, a novel marker of renal function, with risk for developing complications related to peripheral arterial disease (PAD) has not been examined. Methods: We evaluated the hypothesis that a high cystatin C concentration is independently associated with future PAD events among 4025 participants in the Cardiovascular Health Study who underwent serum cystatin C measurement at the visit and who did not have PAD at baseline. The association of cystatin C quintiles with time to first lower-extremity PAD procedure (bypass surgery, angioplasty, or amputation) was evaluated using multivariable proportional hazards models. Secondary analyses were conducted using quintiles of serum creatinine level and estimated glomerular filtration rate (egfr). Results: The annualized risk of undergoing a procedure for PAD was 0.43% per year among participants in the highest cystatin C quintile ( 1.27 mg/l) compared with 0.21% per year or less in all other quintiles. After multivariable adjustment for known risk factors for PAD, elevated cystatin C levels remained associated with the outcome (hazard ratio, 2.5 for highest vs lowest quintile of cystatin C, 95% confidence interval, ). The highest quintiles of serum creatinine level and egfr were not associated with future PAD events in either unadjusted or adjusted analyses. Conclusion: Elevated concentrations of cystatin C were independently predictive of incident PAD events among community-dwelling elderly patients. Arch Intern Med. 2005;165: Author Affiliations are listed at the end of this article. PERIPHERAL ARTERIAL DISEASE (PAD) iscommonintheelderly population and is associated with significant morbidity and mortality. 1,2 Recent data suggest that medical therapies may reduce the risk of amputation and/or revascularization indefinedpopulations. 3-5 Identificationofpatients who are at greatest risk for requiring these procedures may allow targeting of interventions to prevent PAD or slow its progression. A growing number of studies indicate that renal insufficiency is associated with prevalent and incident PAD Cystatin C is a novel serum marker for renal function. It is a cysteine-protease inhibitor that is produced by most human cells, freely filtered by the glomerulus, and subsequently metabolized by the proximal tubule. Concentrations of cystatin C are believed to primarily reflect glomerular filtration rate (GFR). 13 Thus, cystatin C concentration may be a more sensitive indicator of mild renal dysfunction than serum creatinine level. 14 Recent studies have shown that cystatin C is more strongly associated with all-cause and cardiovascular mortality as well as with myocardial infarction, stroke, and congestive heart failure than either serum creatinine or estimated GFR (egfr) We therefore evaluated the hypothesis that a high cystatin C concentration would be independently associated with future PAD events among elderly persons living in the community who did not have prevalent PAD at baseline. We See also page 2659 hypothesized further that this association would be stronger than that for conventional measures of renal function such as serum creatinine level or egfr. METHODS PARTICIPANTS The Cardiovascular Health Study (CHS) is a community-based,longitudinalstudyofmedicareeligibleadults65yearsorolderatbaseline. 18,19 The objective of the study was to evaluate risk factors for the development and progression of cardiovascular disease. The main cohort consisted of 5201 study participants recruited between 1989 and 1990 from 4 US communities: Sacramento County, California; ForsythCounty, NorthCarolina; Washington County, Maryland; and Allegheny County, Pennsylvania. A second cohort of 687AfricanAmericanswasrecruitedin1992and 2666
2 1993. Follow-up interviews for events were conducted semiannually. Cystatin C was measured from frozen samples collected at the visit. A total of 4937 study participants returned for this visit, and serum samples were available for 4734 of these. We excluded 189 participants who had undergone an amputation or revascularization prior to the visit and a further 520 participants who had an ankle-arm index (AAI) of 0.9 or lower at this visit, leaving a study sample of 4025 for the present analysis. MEASUREMENTS All assays were performed on plasma drawn in the morning and stored at 70 C. Cystatin C concentration was measured using a BNII nephelometer (Dade Behring Inc, Deerfield, Ill) using a particle-enhanced immunonephelometric assay (N Latex Cystatin C; Dade Behring Inc, Newark, Del). 20 Polystyrene particles were coated with monoclonal antibodies to cystatin C that agglutinate in the presence of antigen (cystatin C) to cause an increase in the intensity of scattered light. The increase in scattered light is proportional to the amount of cystatin C in the sample. The assay range is to mg/l, with the reference range for young healthy individuals reported as 0.53 to 0.95 mg/l. Intraassay coefficients of variation range from 2.0% to 2.8% and interassay coefficients of variation range from 2.3% to 3.1%. Serum creatinine was measured using the Kodak Ektachem 700 Analyzer (Eastman Kodak, Rochester, NY), a colorimetric method. The AAI is the ratio of ankle to arm systolic blood pressure. The standard protocol for AAI measurement in the CHS has been described previously. 21 Briefly, manual blood pressure measurements were obtained using a Doppler stethoscope (8 MHz; Huntleigh Technology Inc, Luton, Bedfordshire, England) over the right brachial artery and both posterior tibial arteries. To be consistent with prior CHS studies of the association of AAI with cardiovascular outcomes, the AAI was calculated by dividing the lowest leg blood pressure by the blood pressure in the right arm. COVARIATES The primary predictor variable for the present analysis was serum cystatin C concentration at the study visit. This was categorized a priori by quintile, with the lowest quintile serving as the referent category for interquintile comparisons. The association of cystatin C concentration with future PAD events was adjusted for potential confounders, including sociodemographic factors (age, sex, race, and income), prevalent stroke and coronary heart disease (defined as history of myocardial infarction, unstable angina, or angioplasty or coronary artery bypass procedure), and known cardiovascular and PAD risk factors: high body mass index (BMI) (calculated as weight in kilograms divided by the square of height in meters), smoking (current vs past or never), diabetes (history of diabetes, use of hypoglycemic agents or insulin, or fasting glucose 126 mg/dl [ 7.0 mmol/l]), hypertension (systolic blood pressure 140 mm Hg, diastolic blood pressure 90 mm Hg, or use of antihypertensive medications), and abnormal levels of low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides, C-reactive protein, and/or fibrinogen). In secondary analyses, we also measured the unadjusted and adjusted associations with future PAD events of serum creatinine level and egfr, categorized into quintiles. Estimated GFR was determined using the Modification of Diet in Renal Disease formula. 22 STUDY OUTCOME The current analysis examines incident lower-extremity bypass surgery, angioplasty, and amputations for PAD between the visit and June 30, Incident events were identified by International Classification of Diseases, Ninth Revision, Clinical Modification procedure codes for lowerextremity bypass surgery (39.25 or 39.29), lower-extremity amputation ( ), and peripheral angioplasty (39.50 and 39.59, excluding concurrent or 39.61). The study outcome was defined as time from the visit to the first PAD procedure as defined. We selected this severe PAD outcome both to minimize misclassification and because of the clear clinical significance of requiring a procedure for PAD relative to other candidate outcomes such as the development of intermittent claudication or of an AAI less than 0.9. STATISTICAL ANALYSIS We examined the distribution of demographic characteristics, traditional cardiovascular risk factors, prevalent cardiovascular disease, and laboratory measures by quintiles of cystatin C concentration. We generated descriptive summary statistics for each quintile using means (SDs) for continuous variables and proportions for dichotomous variables and calculated P values for linear trend across quintiles. Associations of cystatin C and other predictors with incident PAD events were tested using a Cox proportional hazard model. The proportional hazard assumption was tested using standard residual-based techniques. In secondary analyses, we measured the association of cystatin C with the outcome among participants without prevalent cardiovascular disease at baseline, and we measured the respective associations of creatinine level and egfr with PAD events. All analyses were performed using S-Plus (release 6.1; Insightful Inc, Seattle, Wash) and SPSS statistical software (release ; SPSS Inc, Chicago, Ill). P.05 was considered statistically significant. RESULTS Across cystatin C quintiles, mean age and serum creatinine level increased. The percentage of African Americans decreased across quintiles. Most other established cardiovascular disease risk factors (male sex, hypertension, high BMI, and abnormal levels of triglycerides, C-reactive protein, and fibrinogen) and the prevalence of preexisting cardiovascular disease also increased across cystatin C quintiles (Table 1). Serum levels of LDL-C and HDL-C decreased across cystatin C quintiles. There was a U-shaped relationship between diabetes and cystatin C concentration. The distributions of AAI and smoking history did not differ significantly across cystatin C quintiles in this sample. Of the 4025 CHS participants included in this analysis, 1192 died, 980 underwent non-pad cardiovascular events, and 60 underwent a PAD procedure during followup. The annualized risk of undergoing a procedure for PAD was 0.43% per year among participants in the highest cystatin C quintile ( 1.27 mg/l) compared with 0.21% per year or less in all other quintiles (Figure and Table 2). Annualized risk did not increase appreciably across quintiles of either creatinine level or egfr (Figure). In both unadjusted and adjusted analyses, participants with a cystatin C concentration in the highest quintile had an increased risk of requiring a PAD procedure compared with participants in the lowest cystatin C quintile (Table 2). Cystatin C was still associated with the outcome when we excluded cohort members with prevalent cardiovascular disease at baseline (hazard ratio [HR], 1.33; 95% confidence interval [CI] per stan- 2667
3 Table 1. Participant Characteristics by Quintile of Cystatin C Concentration* Characteristic 0.90 (n = 874) (n = 809) Cystatin C Concentration, mg/l (n = 839) (n = 785) 1.28 (n = 718) P Value for Trend Age, y 72.8 (4.2) 73.5 (4.5) 74.3 (4.7) 75.3 (5.1) 77.4 (6.0).001 Male 258 (30) 300 (37) 360 (43) 362 (46) 346 (48).001 African American 238 (27) 140 (17) 103 (12) 78 (10) 76 (11).001 Income $ (53) 429 (53) 445 (53) 473 (60) 428 (60).001 History of coronary heart disease 122 (14) 115 (14) 145 (17) 174 (22) 194 (27).001 History of stroke disease 25 (3) 17 (2) 31 (4) 29 (4) 71 (10).001 Hypertension 453 (52) 416 (52) 428 (51) 442 (56) 443 (62).001 Diabetes 138 (16) 95 (12) 96 (11) 114 (15) 122 (17).32 Current smoker 69 (8) 75 (10) 62 (8) 81 (10) 61 (9).44 Body mass index 26.0 (4.5) 26.6 (4.5) 27.0 (4.5) 27.6 (5.2) 27.6 (5.0).001 Creatinine, mg/dl 0.82 (0.16) 0.90 (0.17) 0.97 (0.17) 1.05 (0.19) 1.34 (0.66).001 egfr, ml/min per 1.73 m 2 88 (17) 78 (14) 71 (12) 66 (12) 53 (14).001 LDL cholesterol, mg/dl 127 (33) 127 (32) 127 (33) 128 (34) 123 (35).02 HDL cholesterol, mg/dl 59 (15) 56 (15) 53 (14) 51 (13) 49 (13).001 Triglycerides, mg/dl 103 (78-145) 118 (88-162) 120 (87-168) 131 (97-184) 138 ( ).001 CRP mg/l 1.94 ( ) 2.32 ( ) 2.36 ( ) 2.74 ( ) 3.68 ( ).001 Fibrinogen, mg/dl 316 (62) 317 (62) 321 (61) 334 (68) 345 (75).001 AAI 1.13 (0.11) 1.14 (0.11) 1.15 (0.12) 1.14 (0.13) 1.13 (0.12).09 Abbreviations: AAI, ankle-arm index; CRP, C-reactive protein; egfr, estimated glomerular filtration rate; HDL, high-density lipoprotein; LDL, low-density lipoprotein. SI conversion factors: To convert creatinine to micromoles per liter, multiply by 88.4; HDL and LDL cholesterol to millimoles per liter, multiply by ; and triglycerides to millimoles per liter, multiply by *Data are presented as mean (SD) or median (interquartile range) for continuous variables and number (percentage) for categorical variables. Calculated as weight in kilograms divided by the square of height in meters. Kruskal-Wallis test Creatinine egfr Cystatin C C-reactive protein level, coronary heart disease, and BMI) increased the AUC to 0.72 (95% CI, ). By comparison, the AUC was 0.68 (95% CI, ) for the same model without cystatin C. Event Rate, %/y Lowest Quintiles Highest Figure. Peripheral arterial disease events by quintile of creatinine level, estimated glomerular filtration rate (egfr), and cystatin C. dard deviation of cystatin C). The point estimate for the association of the highest cystatin C quintile with the outcome was also similar in the group without prevalent cardiovascular disease (adjusted HR, 2.31; 95% CI, ). Finally, the associations of quintiles of serum creatinine level and egfr with PAD events were not statistically significant (Table 3). We used receiver operating characteristic (ROC) curves to evaluate the overall ability of cystatin C alone and in conjuction with other significant risk factors to predict risk for PAD events. Cystatin C alone had an area under the ROC curve (AUC) of 0.62 (95% CI, ). Adding the other significant risk factors (diabetes, smoking, COMMENT The present analysis demonstrates that a cystatin C concentration in the highest quintile ( 1.27 mg/l) was independently predictive of future receipt of a PAD procedure among a cohort of elderly community-dwelling adults who did not have PAD at the beginning of follow-up. The association of cystatin C with PAD risk was stronger than with either serum creatinine level or egfr. The finding of an association of cystatin C with future PAD events in participants without prevalent PAD at baseline is consistent with a growing number of studies demonstrating both cross-sectional and longitudinal associations between renal insufficiency and PAD It is unclear whether these associations reflect a causal association or whether impaired renal function is a marker for underlying atherosclerotic disease. An AAI of 0.9 or lower was independently associated with macroalbuminuria in the Strong Heart Study 7 and with elevated serum creatinine levels in the CHS. 21 Indeed, the prevalence of an AAI of 0.9 or lower appears to be extremely high among those with renal insufficiency 6,9,11 and, conversely, renal insufficiency is common among patients with advanced PAD. 23 In addition, several studies have shown that renal insufficiency is associated with the development of claudication among the elderly population and with future ampu- 2668
4 Table 2. Risk of Lower Extremity Bypass, Angioplasty, or Amputation During Follow-up by Quintile of Cystatin C Cystatin C Level, mg/l Subjects, Person-Years at Risk Events, Event Rate, %/y Unadjusted HR Adjusted* HR (Referent) 1.0 (Referent) ( ) 1.1 ( ) ( ) 1.2 ( ) ( ) 1.1 ( ) ( ) 2.5 ( ) Abbreviations: CI, confidence interval; HR, hazard ratio. *Adjusted for age, race, sex, income, hypertension, diabetes, smoking, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, C-reactive protein, myocardial infarction, stroke, triglyceride level, fibrinogen measure, and body mass index (calculated as weight in kilograms divided by the square of height in meters). Table 3. Risk of Lower-Extremity Bypass, Angioplasty, or Amputation During Follow-up by Quintiles of Creatinine Concentration and Estimated GFR Subjects, Person-Years at Risk Events, Event Rate, %/y Unadjusted HR Adjusted HR* Characteristic Creatinine, mg/l 0.75 (Women) (Referent) 1.00 (Referent) 0.95 (Men) (Women) ( ) 0.8 ( ) (Men) (Women) ( ) 1.0 ( ) (Men) (Women) ( ) 0.9 ( ) (Men) 1.05 (Women) ( ) 1.3 ( ) 1.35 (Men) Estimated GFR, ml/min per 1.73 m (Referent) 1.00 (Referent) ( ) 1.5 ( ) ( ) 0.7 ( ) ( ) 1.0 ( ) ( ) 1.7 ( ) Abbreviations: CI, confidence interval; GFR, glomerular filtration rate; HR, hazard ratio. SI conversion factor: To convert creatinine to micromoles per liter, multiply by *Adjusted for age, race, sex, income, hypertension, diabetes, smoking, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, C-reactive protein, myocardial infarction, stroke, triglyceride level, fibrinogen measure, and body mass index (calculated as weight in kilograms divided by the square of height in meters). Creatinine quintiles are sex specific. tation and revascularization events among women with coronary artery disease. 8,12 However, these studies were limited somewhat in that they probably included patients with prevalent PAD. In addition, our findings are consistent with recent studies that reported associations of cystatin C with both mortality and cardiovascular risk in the elderly population, which were stronger than those of serum creatinine level and egfr Most likely, cystatin C is a better predictor of PAD events and other cardiovascular outcomes than serum creatinine level because it is a more accurate measure of renal function, particularly in the elderly. 14,24 In the present study, the risk of lowerextremity PAD procedures did not increase in a stepwise fashion across cystatin C quintiles, as previously reported for all-cause and cardiovascular mortality and incident heart failure, but was increased only at cystatin C levels in the highest quintile. This observation suggests that each specific cardiovascular end point may have a unique association with kidney dysfunction, as measured by cystatin C. The reported association of cystatin C with future PAD events among those without PAD at baseline may have applications in the clinical setting because therapies are available that may reduce the incidence of PAD complications among high-risk patients. Recent studies demonstrate that statins and angiotensin-converting enzyme inhibitors reduce the incidence of lowerextremity amputation and revascularization among highrisk groups. In the MRC\BHF Heart Protection Study 4 a randomized, controlled, clinical trial of the effect of simvastatin on cardiovascular end points among those with high cardiovascular risk randomization to 40-mg simvastatin was associated with a lower incidence of peripheral arterial events during follow-up. This benefit was seen among participants both with and without diabetes and in patients with PAD who had no history of other cardiovascular disease. In the Heart Outcomes Prevention 2669
5 Evaluation (HOPE) Study, 3 randomization to ramipril (vs placebo) was associated with a decreased incidence of lower-extremity revascularization or amputation. The PAD events studied herein are much less common than other cardiovascular outcomes; therefore, methods to target potential preventive therapies to those at greatest risk are particularly important. Further studies are needed to determine whether cystatin C is a useful clinical measure to identify these high-risk patients. Although our results suggest that cystatin C concentration may be a useful clinical measure for identifying patients at greatest risk for future PAD events, these findings have not yet been validated in other cohorts. Furthermore, CHS cohort members were elderly communitydwelling adults, so our findings may not be generalizeable to younger populations. A gold standard measure of renal function is not available for the CHS. Thus, while our results may suggest that cystatin C is a more sensitive marker of renal insufficiency than either serum creatinine level or egfr, it is also possible that the association of cystatin C with PAD events may reflect its association with factors other than level of renal function. 25 In conclusion, cystatin C is independently associated with the development of PAD complications requiring either amputation or revascularization among elderly patients without prevalent PAD at baseline. Further study is needed to determine whether cystatin C may have clinical utility in identifying those at increased risk for requiring a procedure for PAD. Accepted for Publication: July 25, Author Affiliations: Nephrology Division, Department of Medicine (Dr O Hare), and General Internal Medicine Section(Dr Shlipak), Veterans Affairs Medical Center, San Francisco, and Nephrology Division, Department of Medicine (Dr O Hare), and Departments of Medicine and Epidemiology and Biostatistics (Dr Shlipak), University of California, San Francisco; Department of Epidemiology, University of Pittsburgh Graduate School of Public Health, and the Division of Geriatric Medicine(Dr Newman), and the Renal- Electrolyte Division (Dr Fried), University of Pittsburgh School of Medicine, and the Renal Section, Veterans Affairs PittsburghHealthcareSystem(DrFried), Pittsburgh, Pa; CollaborativeHealthStudiesCoordinatingCenter(DrKatz) and Departments of Medicine (Dr Seliger) and Medicine, Epidemiology, and Health Services (Dr Siscovick), University ofwashington, Seattle; andamgeninc, ThousandOaks, Calif (Dr Stehman-Breen). Correspondence: Ann M. O Hare, MD, MA, Box 111J (Nephrology), Veterans Affairs Medical Center, San Francisco, 4150 Clement St, San Francisco, CA (Ann.O Hare@med.va.gov). Financial Disclosure: None. Funding/Support: Dr O Hare is supported by a Research Career Development Award from the Health Services Research Service of Veterans Affairs, and Dr Fried is supported by an Advanced Research Career Development Award from the Medical Research Service of Veterans Affairs. Drs Shlipak, Fried, and Katz are funded by grant R01 HL from The National Heart, Lung, and Blood Institute, Bethesda, Md. Dr Shlipak is also supported by the American Federation for Aging Research and National Institute on Aging (Paul Beeson Scholars Program) and the Robert Wood Johnson Foundation (Generalist Faculty Scholars Program). The Cardiovascular Health Study was supported by contracts N01-HC through N01-HC-85086, N01- HC-35129, and N01 HC from the National Heart, Lung, and Blood Institute. Acknowledgment: We thank Melanie Praught for assistance with Figure 1. A full list of participating CHS investigators and institutions can be found at REFERENCES 1. Criqui MH, Langer RD, Fronek A, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med. 1992;326: Criqui MH, Langer RD, Fronek A, Feigelson HS. Coronary disease and stroke in patients with large-vessel peripheral arterial disease. Drugs. 1991;42(suppl 5): HeartOutcomesPreventionEvaluationStudyInvestigators.Effectsoframipriloncardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet. 2000;355: Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360: Ostergren J, Sleight P, Dagenais G, et al. Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease. Eur Heart J. 2004;25: de Vinuesa SG, Ortega M, Martinez P, Goicoechea M, Campdera FG, Luno J. Subclinical peripheral arterial disease in patients with chronic kidney disease: prevalence and related risk factors. Kidney Int Suppl. 2005;Jan:S44-S Fabsitz RR, Sidawy AN, Go O, et al. Prevalence of peripheral arterial disease and associated risk factors in American Indians: the Strong Heart Study. Am J Epidemiol. 1999;149: Fried LF, Shlipak MG, Crump C, et al. Renal insufficiency as a predictor of cardiovascular outcomes and mortality in elderly individuals. J Am Coll Cardiol. 2003; 41: Leskinen Y, Salenius JP, Lehtimaki T, Huhtala H, Saha H. The prevalence of peripheral arterial disease and medial arterial calcification in patients with chronic renal failure: requirements for diagnostics. Am J Kidney Dis. 2002;40: O Hare A, Johansen K. Lower-extremity peripheral arterial disease among patients with end-stage renal disease. J Am Soc Nephrol. 2001;12: O Hare AM, Glidden DV, Fox CS, Hsu CY. High prevalence of peripheral arterial disease in persons with renal insufficiency: results from the National Health and Nutrition Examination Survey Circulation. 2004;109: O Hare AM, Vittinghoff E, Hsia J, Shlipak MG. Renal insufficiency and the risk of lower extremity peripheral arterial disease: results from the Heart and Estrogen/ Progestin Replacement Study (HERS). J Am Soc Nephrol. 2004;15: Randers E, Kristensen JH, Erlandsen EJ, Danielsen H. Serum cystatin C as a marker of the renal function. Scand J Clin Lab Invest. 1998;58: Fliser D, Ritz E. Serum cystatin C concentration as a marker of renal dysfunction in the elderly. Am J Kidney Dis. 2001;37: Sarnak MJ, Katz R, Stehman-Breen CO, et al. Cystatin C concentration as a risk factor for heart failure in older adults. Ann Intern Med. 2005;142: Shlipak MG, Sarnak MJ, Katz R, et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med. 2005;352: Shlipak MG, Katz R, Fried LF, et al. Cystatin-C and mortality in elderly persons with heart failure. J Am Coll Cardiol. 2005;45: Fried LP, Borhani NO, Enright P, et al. The Cardiovascular Health Study: design and rationale. Ann Epidemiol. 1991;1: Tell GS, Fried LP, Hermanson B, Manolio TA, Newman AB, Borhani NO. Recruitment of adults 65 years and older as participants in the Cardiovascular Health Study. Ann Epidemiol. 1993;3: Wasen E, Isoaho R, Mattila K, Vahlberg T, Kivela SL, Irjala K. Estimation of glomerular filtration rate in the elderly: a comparison of creatinine-based formulae with serum cystatin C. J Intern Med. 2004;256: Newman AB, Siscovick DS, Manolio TA, et al. Ankle-arm index as a marker of atherosclerosis in the Cardiovascular Health Study. Circulation. 1993;88: Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med. 1999;130: O Hare AM, Bertenthal D, Shlipak MG, Sen S, Chren MM. Impact of renal insufficiency on mortality in advanced lower extremity peripheral arterial disease. J Am Soc Nephrol. 2005;16: Herget-Rosenthal S, Trabold S, Pietruck F, Holtmann M, Philipp T, Kribben A. Cystatin C: efficacy as screening test for reduced glomerular filtration rate. Am J Nephrol. 2000;20: Knight EL, Verhave JC, Spiegelman D, et al. Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int. 2004;65:
ORIGINAL INVESTIGATION. C-Reactive Protein Concentration and Incident Hypertension in Young Adults
ORIGINAL INVESTIGATION C-Reactive Protein Concentration and Incident Hypertension in Young Adults The CARDIA Study Susan G. Lakoski, MD, MS; David M. Herrington, MD, MHS; David M. Siscovick, MD, MPH; Stephen
More informationCystatin-C and inflammatory markers in the ambulatory elderly
The American Journal of Medicine (2005) 118, 1416.e25-1416.e31 CLINICAL RESEARCH STUDY Cystatin-C and inflammatory markers in the ambulatory elderly Michael G. Shlipak, MD, MPH, a Ronit Katz, PhD, b Mary
More informationThere is a high prevalence of chronic kidney disease
CLINICAL INVESTIGATIONS Kidney Function and Mortality in Octogenarians: Cardiovascular Health Study All Stars Shani Shastri, MD, MPH, MS, a Ronit Katz, DPhil, b Dena E. Rifkin, MD, MS, c Linda F. Fried,
More informationjournal of medicine The new england Cystatin C and the Risk of Death and Cardiovascular Events among Elderly Persons abstract
The new england journal of medicine established in 1812 may 19, 2005 vol. 352 no. 20 Cystatin C and the Risk of Death and Cardiovascular Events among Elderly Persons Michael G. Shlipak, M.D., M.P.H., Mark
More informationChronic kidney disease (CKD) has received
Participant Follow-up in the Kidney Early Evaluation Program (KEEP) After Initial Detection Allan J. Collins, MD, FACP, 1,2 Suying Li, PhD, 1 Shu-Cheng Chen, MS, 1 and Joseph A. Vassalotti, MD 3,4 Background:
More informationRenal Insufficiency and Use of Revascularization among a National Cohort of Men with Advanced Lower Extremity Peripheral Arterial Disease
Renal Insufficiency and Use of Revascularization among a National Cohort of Men with Advanced Lower Extremity Peripheral Arterial Disease Ann M. O Hare,* Daniel Bertenthal, Anton N. Sidawy,** Michael G.
More informationAGING KIDNEY IN HIV DISEASE
AGING KIDNEY IN HIV DISEASE Michael G. Shlipak, MD, MPH Professor of Medicine, Epidemiology and Biostatistics, UCSF Chief, General Internal Medicine, San Francisco VA Medical Center Kidney, Aging and HIV
More informationCJASN epress. Published on January 4, 2006 as doi: /CJN
CJASN epress. Published on January 4, 2006 as doi: 10.2215/CJN.01070905 Renal Insufficiency and Use of Revascularization among a National Cohort of Men with Advanced Lower Extremity Peripheral Arterial
More informationA: Epidemiology update. Evidence that LDL-C and CRP identify different high-risk groups
A: Epidemiology update Evidence that LDL-C and CRP identify different high-risk groups Women (n = 27,939; mean age 54.7 years) who were free of symptomatic cardiovascular (CV) disease at baseline were
More informationIn the general population, patients with peripheral arterial
Impact of Renal Insufficiency on Mortality in Advanced Lower Extremity Peripheral Arterial Disease Ann M. O Hare,* Daniel Bertenthal, Michael G. Shlipak, Saunak Sen, Mary-Margaret Chren *Divisions of Nephrology
More informationSupplementary Table 1. Baseline Characteristics by Quintiles of Systolic and Diastolic Blood Pressures
Supplementary Data Supplementary Table 1. Baseline Characteristics by Quintiles of Systolic and Diastolic Blood Pressures Quintiles of Systolic Blood Pressure Quintiles of Diastolic Blood Pressure Q1 Q2
More informationEffects of Kidney Disease on Cardiovascular Morbidity and Mortality
Effects of Kidney Disease on Cardiovascular Morbidity and Mortality Joachim H. Ix, MD, MAS Assistant Professor in Residence Division of Nephrology University of California San Diego, and Veterans Affairs
More informationegfr > 50 (n = 13,916)
Saxagliptin and Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Moderate or Severe Renal Impairment: Observations from the SAVOR-TIMI 53 Trial Supplementary Table 1. Characteristics according
More informationGALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS
GALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS Table of Contents List of authors pag 2 Supplemental figure I pag 3 Supplemental figure II pag 4 Supplemental
More informationSupplementary Online Content
Supplementary Online Content Kavousi M, Leening MJG, Nanchen D, et al. Comparison of application of the ACC/AHA guidelines, Adult Treatment Panel III guidelines, and European Society of Cardiology guidelines
More informationInternational Journal of Pharma and Bio Sciences IS CYSTATIN C ESTIMATION A BETTER MARKER IN CHRONIC KIDNEY DISEASE PATIENTS?
International Journal of Pharma and Bio Sciences RESEARCH ARTICLE BIO CHEMISTRY IS CYSTATIN C ESTIMATION A BETTER MARKER IN CHRONIC KIDNEY DISEASE PATIENTS? Corresponding Author R.KUMARESAN Department
More informationThe JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009
The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 Learning Objectives 1. Understand the role of statin therapy in the primary and secondary prevention of stroke 2. Explain
More informationCorrelation of novel cardiac marker
Correlation of novel cardiac marker and mortality in EGAT population. Soluble ST2 hscrp Poh Chanyavanich, MD SukitYamwong, MD Piyamitr Sritara, MD Ramathibodi hospital Background hscrp - the most widely
More informationCVD risk assessment using risk scores in primary and secondary prevention
CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities
More informationSerum uric acid levels improve prediction of incident Type 2 Diabetes in individuals with impaired fasting glucose: The Rancho Bernardo Study
Diabetes Care Publish Ahead of Print, published online June 9, 2009 Serum uric acid and incident DM2 Serum uric acid levels improve prediction of incident Type 2 Diabetes in individuals with impaired fasting
More informationCardiovascular Risk Among Adults With Chronic Kidney Disease, With or Without Prior Myocardial Infarction
Journal of the American College of Cardiology Vol. 48, No. 6, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2006.05.047
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Weintraub WS, Grau-Sepulveda MV, Weiss JM, et al. Comparative
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and
More informationOutline. Outline CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW 7/23/2013. Question 1: Which of these patients has CKD?
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationOutline. Outline CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW. Question 1: Which of these patients has CKD?
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationjournal of medicine The new england Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein Abstract
The new england journal of medicine established in 1812 november 20, 2008 vol. 359 no. 21 to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein Paul M Ridker, M.D., Eleanor Danielson,
More informationORIGINAL INVESTIGATION. Fasting and 2-Hour Postchallenge Serum Glucose Measures and Risk of Incident Cardiovascular Events in the Elderly
Fasting and 2-Hour Postchallenge Serum Glucose Measures and Risk of Incident Cardiovascular Events in the Elderly The Cardiovascular Health Study ORIGINAL INVESTIGATION Nicholas L. Smith, PhD, MPH; Joshua
More informationJUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study
Panel Discussion: Literature that Should Have an Impact on our Practice: The Study Kaiser COAST 11 th Annual Conference Maui, August 2009 Robert Blumberg, MD, FACC Ralph Brindis, MD, MPH, FACC Primary
More informationCystatin C, Albuminuria, and Mortality Among Older Adults With Diabetes
Epidemiology/Health Services Research O R I G I N A L A R T I C L E Cystatin C, Albuminuria, and Mortality Among Older Adults With Diabetes IAN H. DE BOER, MD, MS 1 RONIT KATZ, DPHIL 1 JIE J. CAO, MD,
More informationCystatin C, Left Ventricular Hypertrophy, and Diastolic Dysfunction: Data From the Heart and Soul Study
Journal of Cardiac Failure Vol. 12 No. 8 2006 Cystatin C, Left Ventricular Hypertrophy, and Diastolic Dysfunction: Data From the Heart and Soul Study JOACHIM H. IX, MD, 1,2 MICHAEL G. SHLIPAK, MD, MPH,
More informationCVD Prevention, Who to Consider
Continuing Professional Development 3rd annual McGill CME Cruise September 20 27, 2015 CVD Prevention, Who to Consider Dr. Guy Tremblay Excellence in Health Care and Lifelong Learning Global CV risk assessment..
More informationCARDIOVASCULAR RISK ASSESSMENT ADDITION OF CHRONIC KIDNEY DISEASE AND RACE TO THE FRAMINGHAM EQUATION PAUL E. DRAWZ, MD, MHS
CARDIOVASCULAR RISK ASSESSMENT ADDITION OF CHRONIC KIDNEY DISEASE AND RACE TO THE FRAMINGHAM EQUATION by PAUL E. DRAWZ, MD, MHS Submitted in partial fulfillment of the requirements for the degree of Master
More informationThe Framingham Coronary Heart Disease Risk Score
Plasma Concentration of C-Reactive Protein and the Calculated Framingham Coronary Heart Disease Risk Score Michelle A. Albert, MD, MPH; Robert J. Glynn, PhD; Paul M Ridker, MD, MPH Background Although
More informationCystatin C, albuminuria, and mortality among older adults with diabetes mellitus
Diabetes Care Publish Ahead of Print, published online July 8, 2009 Cystatin C, albuminuria, and mortality Cystatin C, albuminuria, and mortality among older adults with diabetes mellitus Ian H. de Boer,
More informationSerum Creatinine and Blood Urea Nitrogen Levels in Patients with Coronary Artery Disease
Serum Creatinine and Blood Urea Nitrogen Levels in Patients with Coronary Artery Disease MAK Akanda 1, KN Choudhury 2, MZ Ali 1, MK Kabir 3, LN Begum 4, LA Sayami 1 1 National Institute of Cardiovascular
More informationSupplementary Online Content
Supplementary Online Content Leibowitz M, Karpati T, Cohen-Stavi CJ, et al. Association between achieved low-density lipoprotein levels and major adverse cardiac events in patients with stable ischemic
More informationOutline. Outline 10/14/2014 CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW. Question 1: Which of these patients has CKD?
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationEarly risk stratification is essential in the management of
Cystatin C A Novel Predictor of Outcome in Suspected or Confirmed Non ST-Elevation Acute Coronary Syndrome Tomas Jernberg, MD, PhD; Bertil Lindahl, MD, PhD; Stefan James, MD, PhD; Anders Larsson, MD, PhD;
More informationAnnals of Epidemiology
Annals of Epidemiology 23 (2013) 106e111 Contents lists available at SciVerse ScienceDirect Annals of Epidemiology journal homepage: www.annalsofepidemiology.org Hypertension and low HDL cholesterol were
More informationSerum levels of galectin-1, galectin-3, and galectin-9 are associated with large artery atherosclerotic
Supplementary Information The title of the manuscript Serum levels of galectin-1, galectin-3, and galectin-9 are associated with large artery atherosclerotic stroke Xin-Wei He 1, Wei-Ling Li 1, Cai Li
More informationUpdate on Lipid Management in Cardiovascular Disease: How to Understand and Implement the New ACC/AHA Guidelines
Update on Lipid Management in Cardiovascular Disease: How to Understand and Implement the New ACC/AHA Guidelines Paul Mahoney, MD Sentara Cardiology Specialists Lipid Management in Cardiovascular Disease
More informationMild to moderate reductions in kidney function are
Annals of Internal Medicine Article Cystatin C as a Risk Factor for Outcomes in Chronic Kidney Disease Vandana Menon, MD, PhD; Michael G. Shlipak, MD, MPH; Xuelei Wang, MS; Josef Coresh, MD, PhD; Tom Greene,
More informationDisclosures. Outline. Outline 5/23/17 CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Solomon SD, Uno H, Lewis EF, et al. Erythropoietic response
More information(n=6279). Continuous variables are reported as mean with 95% confidence interval and T1 T2 T3. Number of subjects
Table 1. Distribution of baseline characteristics across tertiles of OPG adjusted for age and sex (n=6279). Continuous variables are reported as mean with 95% confidence interval and categorical values
More informationDisclosures. Outline. Outline 7/27/2017 CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Rawshani Aidin, Rawshani Araz, Franzén S, et al. Risk factors,
More informationACCP Cardiology PRN Journal Club
ACCP Cardiology PRN Journal Club Announcements Next journal club Thursday, Dec. 14 th at 3:00 PM EST PACIFY Trial Effects of IV Fentanyl on Ticagrelor Absorption and Platelet Inhibition Among Patients
More informationSupplementary Online Content
Supplementary Online Content Pedersen SB, Langsted A, Nordestgaard BG. Nonfasting mild-to-moderate hypertriglyceridemia and risk of acute pancreatitis. JAMA Intern Med. Published online November 7, 2016.
More informationIntensive Treatment of Diabetes is Associated with a Reduced Rate of Peripheral Arterial Calcification in Diabetes Control and Complications Trial
Diabetes Care Publish Ahead of Print, published online July 10, 2007 Intensive Treatment of Diabetes is Associated with a Reduced Rate of Peripheral Arterial Calcification in Diabetes Control and Complications
More informationJOURNAL OF VASCULAR SURGERY Volume 32, Number 6 McDermott et al 1165 METHODS
Lower ankle/brachial index, as calculated by averaging the dorsalis pedis and posterior tibial arterial pressures, and association with leg functioning in peripheral arterial disease Mary McGrae McDermott,
More informationAPPENDIX AVAILABLE ON THE HEI WEB SITE
APPENDIX AVAILABLE ON THE HEI WEB SITE Research Report 178 National Particle Component Toxicity (NPACT) Initiative Report on Cardiovascular Effects Sverre Vedal et al. Section 1: NPACT Epidemiologic Study
More informationResearch Article Preinterventional Cystatin C: A Highly Prognostic Marker for All-Cause Mortality after Coronarography
Advances in Nephrology, Article ID 510209, 6 pages http://dx.doi.org/10.1155/2014/510209 Research Article Preinterventional Cystatin C: A Highly Prognostic Marker for All-Cause Mortality after Coronarography
More informationAutonomic nervous system, inflammation and preclinical carotid atherosclerosis in depressed subjects with coronary risk factors
Autonomic nervous system, inflammation and preclinical carotid atherosclerosis in depressed subjects with coronary risk factors Carmine Pizzi 1 ; Lamberto Manzoli 2, Stefano Mancini 3 ; Gigliola Bedetti
More informationThe CARI Guidelines Caring for Australians with Renal Impairment. Cardiovascular Risk Factors
Cardiovascular Risk Factors ROB WALKER (Dunedin, New Zealand) Lipid-lowering therapy in patients with chronic kidney disease Date written: January 2005 Final submission: August 2005 Author: Rob Walker
More informationThe Association Between Cystatin C and Frailty Status in Older Men
The Association Between Cystatin C and Frailty Status in Older Men A THESIS SUBMITTED TO THE FACULTY OF THE GRADUATE SCHOOL OF THE UNIVERSITY OF MINNESOTA BY Allyson Hart IN PARTIAL FULFILLMENT OF THE
More informationFibroblast Growth Factor-23 and Death, Heart Failure, and Cardiovascular Events in Community-Living Individuals
Journal of the American College of Cardiology Vol. 60, No. 3, 2012 2012 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.03.040
More informationClinical Features and Subtypes of Ischemic Stroke Associated with Peripheral Arterial Disease
Cronicon OPEN ACCESS EC NEUROLOGY Research Article Clinical Features and Subtypes of Ischemic Stroke Associated with Peripheral Arterial Disease Jin Ok Kim, Hyung-IL Kim, Jae Guk Kim, Hanna Choi, Sung-Yeon
More informationBariatric Surgery versus Intensive Medical Therapy for Diabetes 3-Year Outcomes
The new england journal of medicine original article Bariatric Surgery versus Intensive Medical for Diabetes 3-Year Outcomes Philip R. Schauer, M.D., Deepak L. Bhatt, M.D., M.P.H., John P. Kirwan, Ph.D.,
More informationKidney Function and Systolic Blood Pressure New Insights From Cystatin C: Data from the Heart and Soul Study
AJH 2006; 19:939 946 Kidney Function and Systolic Blood Pressure New Insights From Cystatin C: Data from the Heart and Soul Study Kidney Carmen A. Peralta, Mary A. Whooley, Joachim H. Ix, and Michael G.
More informationARIC Manuscript Proposal # PC Reviewed: 2/10/09 Status: A Priority: 2 SC Reviewed: Status: Priority:
ARIC Manuscript Proposal # 1475 PC Reviewed: 2/10/09 Status: A Priority: 2 SC Reviewed: Status: Priority: 1.a. Full Title: Hypertension, left ventricular hypertrophy, and risk of incident hospitalized
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the
More informationSupplementary Online Content
Supplementary Online Content Afkarian M, Zelnick L, Hall YN, et al. Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014. JAMA. doi:10.1001/jama.2016.10924 emethods efigure
More informationAndrejs Kalvelis 1, MD, PhD, Inga Stukena 2, MD, Guntis Bahs 3 MD, PhD & Aivars Lejnieks 4, MD, PhD ABSTRACT INTRODUCTION. Riga Stradins University
CARDIOVASCULAR RISK FACTORS ORIGINAL ARTICLE Do We Correctly Assess the Risk of Cardiovascular Disease? Characteristics of Risk Factors for Cardiovascular Disease Depending on the Sex and Age of Patients
More informationMacrovascular Residual Risk. What risk remains after LDL-C management and intensive therapy?
Macrovascular Residual Risk What risk remains after LDL-C management and intensive therapy? Defining Residual Vascular Risk The risk of macrovascular events and microvascular complications which persists
More informationCardiovascular Diabetology. Open Access ORIGINAL INVESTIGATION. C. R. L. Cardoso 1, N. C. Leite 1, C. B. M. Moram 2 and G. F.
https://doi.org/10.1186/s12933-018-0677-0 Cardiovascular Diabetology ORIGINAL INVESTIGATION Open Access Long term visit to visit glycemic variability as predictor of micro and macrovascular complications
More informationSUPPLEMENTARY DATA. Supplementary Table 1. Baseline Patient Characteristics
Supplementary Table 1. Baseline Patient Characteristics Normally distributed data are presented as mean (±SD), data that were not of a normal distribution are presented as median (ICR). The baseline characteristics
More informationCardiovascular Diseases in CKD
1 Cardiovascular Diseases in CKD Hung-Chun Chen, MD, PhD. Kaohsiung Medical University Taiwan Society of Nephrology 1 2 High Prevalence of CVD in CKD & ESRD Foley RN et al, AJKD 1998; 32(suppl 3):S112-9
More informationClinical Investigations
Clinical Investigations Association of Cystatin C with Ischemia in Patients with Coronary Heart Disease Address for correspondence: Rajat Deo, MD 3400 Spruce Street 9 Founders Cardiology Philadelphia,
More informationAntihypertensive Trial Design ALLHAT
1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes
More informationKidney and heart: dangerous liaisons. Luis M. RUILOPE (Madrid, Spain)
Kidney and heart: dangerous liaisons Luis M. RUILOPE (Madrid, Spain) Type 2 diabetes and renal disease: impact on cardiovascular outcomes The "heavyweights" of modifiable CVD risk factors Hypertension
More informationIntermediate Methods in Epidemiology Exercise No. 4 - Passive smoking and atherosclerosis
Intermediate Methods in Epidemiology 2008 Exercise No. 4 - Passive smoking and atherosclerosis The purpose of this exercise is to allow students to recapitulate issues discussed throughout the course which
More informationHigh-sensitivity Troponin T Predicts Recurrent Cardiovascular Events in Patients with Stable Coronary Heart Disease: KAROLA Study 8 Year FU
ESC Congress 2011 Paris, France, August 27-31 KAROLA Session: Prevention: Are biomarkers worth their money? Abstract # 84698 High-sensitivity Troponin T Predicts Recurrent Cardiovascular Events in Patients
More informationLucia Cea Soriano 1, Saga Johansson 2, Bergur Stefansson 2 and Luis A García Rodríguez 1*
Cea Soriano et al. Cardiovascular Diabetology (2015) 14:38 DOI 10.1186/s12933-015-0204-5 CARDIO VASCULAR DIABETOLOGY ORIGINAL INVESTIGATION Open Access Cardiovascular events and all-cause mortality in
More informationS150 KEEP Analytical Methods. American Journal of Kidney Diseases, Vol 55, No 3, Suppl 2, 2010:pp S150-S153
S150 KEEP 2009 Analytical Methods American Journal of Kidney Diseases, Vol 55, No 3, Suppl 2, 2010:pp S150-S153 S151 The Kidney Early Evaluation program (KEEP) is a free, communitybased health screening
More informationThe Diabetes Link to Heart Disease
The Diabetes Link to Heart Disease Anthony Abe DeSantis, MD September 18, 2015 University of WA Division of Metabolism, Endocrinology and Nutrition Oswald Toosweet Case #1 68 yo M with T2DM Diagnosed DM
More informationORIGINAL INVESTIGATION. Relation of Triglyceride Levels, Fasting and Nonfasting, to Fatal and Nonfatal Coronary Heart Disease
ORIGINAL INVESTIGATION Relation of Triglyceride Levels, Fasting and Nonfasting, to Fatal and Nonfatal Coronary Heart Disease Lynn E. Eberly, PhD; Jeremiah Stamler, MD; James D. Neaton, PhD; for the Multiple
More informationMetabolic syndrome is a constellation of cardiovascular
and Cognitive Decline in Elderly Latinos: Findings from the Sacramento Area Latino Study of Aging Study Kristine Yaffe, MD, wzk Mary Haan, DrPH, MPH, z Terri Blackwell, MA, # Elena Cherkasova, BA, Rachel
More informationCardiovascular Complications of Diabetes
VBWG Cardiovascular Complications of Diabetes Nicola Abate, M.D., F.N.L.A. Professor and Chief Division of Endocrinology and Metabolism The University of Texas Medical Branch Galveston, Texas Coronary
More informationJohn J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam
Latest Insights from the JUPITER Study John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Inflammation, hscrp, and Vascular Prevention
More informationCHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationCHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH SCIENTIFIC DIRECTOR KIDNEY HEALTH RESEARCH COLLABORATIVE - UCSF CHIEF - GENERAL INTERNAL MEDICINE, SAN FRANCISCO
More informationSTABILITY Stabilization of Atherosclerotic plaque By Initiation of darapladib TherapY. Harvey D White on behalf of The STABILITY Investigators
STABILITY Stabilization of Atherosclerotic plaque By Initiation of darapladib TherapY Harvey D White on behalf of The STABILITY Investigators Lipoprotein- associated Phospholipase A 2 (Lp-PLA 2 ) activity:
More informationPrevention And Treatment of Diabetic Nephropathy. MOH Clinical Practice Guidelines 3/2006 Dr Stephen Chew Tec Huan
Prevention And Treatment of Diabetic Nephropathy MOH Clinical Practice Guidelines 3/2006 Dr Stephen Chew Tec Huan Prevention Tight glucose control reduces the development of diabetic nephropathy Progression
More informationVal-MARC: Valsartan-Managing Blood Pressure Aggressively and Evaluating Reductions in hs-crp
Página 1 de 5 Return to Medscape coverage of: American Society of Hypertension 21st Annual Scientific Meeting and Exposition Val-MARC: Valsartan-Managing Blood Pressure Aggressively and Evaluating Reductions
More informationNew Guidelines in Dyslipidemia Management
The Fourth IAS-OSLA Course on Lipid Metabolism and Cardiovascular Risk Muscat, Oman, February 2018 New Guidelines in Dyslipidemia Management Dr. Khalid Al-Waili, MD, FRCPC, DABCL Senior Consultant Medical
More informationBlood Pressure Monitoring in Chronic Kidney Disease
Blood Pressure Monitoring in Chronic Kidney Disease Aldo J. Peixoto, MD FASN FASH Associate Professor of Medicine (Nephrology), YSM Associate Chief of Medicine, VACT Director of Hypertension, VACT American
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE General practice Indicators for the NICE menu
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE General practice Indicators for the NICE menu Indicator area: Pulse rhythm assessment for AF Indicator: NM146 Date: June 2017 Introduction There is evidence
More informationEmmanouil S. Brilakis 1{, Joseph P. McConnell 2, Ryan J. Lennon 3, Ahmad A. Elesber 1, Jeffrey G. Meyer 2, and Peter B. Berger 4 * Introduction
European Heart Journal (2005) 26, 137 144 doi:10.1093/eurheartj/ehi010 Clinical research Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic
More informationOutline. Outline. Introduction CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW 8/11/2011
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationJASN Express. Published on October 19, 2005 as doi: /ASN
JASN Express. Published on October 19, 2005 as doi: 10.1681/ASN.2005010006 Cystatin C and Subclinical Brain Infarction Stephen L. Seliger,* W.T. Longstreth Jr., Ronit Katz, Teri Manolio, Linda F. Fried,
More informationHeart Failure and Cardio-Renal Syndrome 1: Pathophysiology. Biomarkers of Renal Injury and Dysfunction
CRRT 2011 San Diego, CA 22-25 February 2011 Heart Failure and Cardio-Renal Syndrome 1: Pathophysiology Biomarkers of Renal Injury and Dysfunction Dinna Cruz, M.D., M.P.H. Department of Nephrology San Bortolo
More informationReducing proteinuria
Date written: May 2005 Final submission: October 2005 Author: Adrian Gillin Reducing proteinuria GUIDELINES a. The beneficial effect of treatment regimens that include angiotensinconverting enzyme inhibitors
More informationHHS Public Access Author manuscript Am J Kidney Dis. Author manuscript; available in PMC 2017 July 05.
HHS Public Access Author manuscript Published in final edited form as: Am J Kidney Dis. 2017 March ; 69(3): 482 484. doi:10.1053/j.ajkd.2016.10.021. Performance of the Chronic Kidney Disease Epidemiology
More informationSoo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital
Soo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital Agenda Association between Cardiovascular Disease and Type 2 Diabetes Importance of HbA1c Management esp. High risk patients
More informationLow ALT Levels Independently Associated with 22-Year All-Cause Mortality Among Coronary Heart Disease Patients
Low ALT Levels Independently Associated with 22-Year All-Cause Mortality Among Coronary Heart Disease Patients N. Peltz-Sinvani, MD 1,4,R.Klempfner,MD 2,4, E. Ramaty, MD 1,4,B.A.Sela,PhD 3,4,I.Goldenberg,MD
More informationWhat have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline?
What have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline? Salim S. Virani, MD, PhD, FACC, FAHA Associate Professor, Section of Cardiovascular Research Baylor
More informationSupplementary Online Content
Supplementary Online Content Larsen JR, Vedtofte L, Jakobsen MSL, et al. Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine- or olanzapine-treated patients with schizophrenia
More informationUric Acid and Incident Kidney Disease in the Community
CLINICAL EPIDEMIOLOGY www.jasn.org Uric Acid and Incident Kidney Disease in the Community Daniel E. Weiner,* Hocine Tighiouart, Essam F. Elsayed,* John L. Griffith, Deeb N. Salem, and Andrew S. Levey*
More information